An immunotherapy drug could spare bowel cancer patients the need for surgery after results showed it was effective in 100% of cases. Jemperli (also called dostarlimab) from British pharmaceutical company GSK showed “unprecedented results”, the firm said, with no evidence of disease in all patients treated. Everyone on the drug had locally advanced mismatch repair deficient (dMMR) rectal cancer, a form of bowel cancer, according to data presented at the American Society of Clinical Oncology (ASCO) conference in Chicago. The data showed all 42 patients in a trial led by Memorial Sloan Kettering …